Recombinant SSP4 protein from Trypanosoma cruzi amastigotes regulates nitric oxide production by macrophages

Parasite Immunology

Volumn 26, Issue 10, 2004, Pages 409-418

  Ramos Ligonio, A ^a   Lopez Monteon A ^a   Talamas Rohana P ^a   Rosales Encina, Jose Luis ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Cytokines; Macrophage; Nitric oxide; Recombinant protein; TcSSP4

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PARASITE ANTIGEN; PROTEIN SSP4; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE; TRYPANOSOMA CRUZI; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TRYPANOSOMA CRUZI;

ANIMALIA; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 14944353509     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9838.2004.00729.x     Document Type: Article

References (65)

1. Takle GB & Snary D. In Immunology of Parasitic Infections, Warren KS (ed.): Immunology of Parasitic Infections. Oxford: Blackwell Scientific Publications; 1993: 213.
2. Minoprio P, El-Cheikh M, Murphy E et al. Xid-associated resistance to experimental Chagas' disease is IFN-gamma dependent. J Immunol 1993; 151: 4200-4208.
3. Rottenberg M, Lindqvist C, Koman A, Segura EL & Orn A. Modulation of both interleukin-2-receptor expression and interleukin-2-production during experimental murine Trypanosoma cruzi. Scan J Immunol 1989; 30: 65-72.
4. McCabe RE, Meagher SG & Mullins BT. Endogenous interferon-gamma, macrophage activation, and murine host defense against acute infection with Trypanosoma cruzi. J Infect Dis 1991; 163: 912-915.
5. Mosmann T & Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
6. Minoprio P, Itohara S, Heusser C, Tonegawa S & Coutinho A. Immunobiology of murine Trypanosoma cruzi infection: the predominance of parasite-nonspecific response and the activation of TcR1 T cells. Immunol Rev 1989; 112: 183-207.
7. Reed S, Brownell C, Russo D, Silva J, Grabstein K & Morrissey P. IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol 1994; 153: 3135-3140.
8. Zhang L & Tarleton R. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemestry: Lack of association between susceptibility and type 2 cytokine production. Eur J Immunol 1996; 26: 102-109.
9. Cardillo F, Voltarelli JC, Reed SG & Silva JS. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun 1995; 64: 128-134.
10. Holscher C, Kohler G, Muller U, Mossmann H, Schaub GA & Brombacher F. Defective nitric oxide effectors functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor of inducible nitric oxide synthase. Infect Immun 1998; 66: 1208-1215.
11. Vespa G, Cunha F & Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 1994; 62: 5177-5182.
12. Aliberti JE, Cardoso MA, Martins GA & Silva JS. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 1996; 64: 1961-1967.
13. Ding AH, Nathan CF, Graycar J, Derynck R, Stuehr DJ & Srimal S. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokine and evidence for independent production. J Immunol 1988; 141: 2407-2412.
14. Moncada S, Palmer JR & Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
15. Adams L, Hibbs B, Taintor RR & Kraheenbuhl JL. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii: role of synthesis of inorganic nitrogen from L-arginine. J Immunol 1990; 144: 2725-2729.
16. Gazzinelli RT, Oswald I, Hieny S, James S & Sher A. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves and L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol 1992; 22: 2501-2506.
17. Gregory S, Wing E, Hoffman R & Simmons RL. Reactive nitrogen intermediates suppress the primary immunologic response to Listeria. J Immunol 1993; 150: 2901-2909.
18. Chan J, Tanaka K, Carrol D, Flynn J & Bloom BR. Effects of nitric oxide synthase inhibitors on murine infections with Mycobacterium tuberculosis. Infect Immun 1995; 63: 736-740.
19. Gregory S, Wing E, Hoffman R & Simmons RL. Reactive nitrogen intermediates suppress the primary immunologic response to Listeria. J Immunol 1993; 150: 2901-2909.
20. Sasaki S, Miura T, Nishikawa S, Yamada K, Hirause M & Nakane A. Protective role of nitric oxide in Staphylococcus aureus infection in mice. Infect Immun 1998; 66: 1017-1022.
21. Xie Q, Kawakami K, Kudeken N, Zhang T, Qureshi M & Saito A. Different susceptibility of three clinically isolated strains of Cryptococcus neoformans to the fungicidal effects of reactive nitrogen and oxygen intermediates: possible relationships with virulence. Microbiol Immunol 1997; 41: 725-731.
22. Abrahamson I & Coffman R. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol 1995; 155: 3955-3961.
23. Candolfi E, Hunter C & Remington JS. Mitogen and antigen specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect Immun 1994; 62: 1995-2001.
24. Rockett K, Awburn MM, Rockett EJ, Cowden WB & Clark IA. Possible role of nitric oxide in malarial immunosuppression. Parasite Immunol 1994; 16: 243-249.
25. Sternberg J & Mabbott NA. Nitric oxide-mediated suppression of T cell responses during Trypanosoma brucei infection: soluble trypanosome products and interferon-γ are synergistic inducers of nitric oxide synthase. Eur J Immunol 1996; 26: 539-248.
26. Munoz-Fernandez MA, Fernández MA & Fresno M. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol 1992; 22: 301-307.
27. Petray P, Rottenberg M, Grinstein S & Orn A. Release of nitric oxide during the experimental infection with Trypanosoma cruzi. Parasite Immunol 1994; 16: 193-199.
28. Fernandez-Gomez R, Esteban S, Gomez-Corvera R, Zoulika K & Ouaissi A. Trypanosoma cruzi: Tc52 released protein-induced increased expression of nitric oxide synthase and nitric oxide production by macrophages. J Immunol 1998; 160: 3471-3479.
29. Andrews NW, Hong KS, Robbins ES & Nussenzweig V. Stage-specific surface antigen expressed during the morphogenesis of vertebrate forms of Trypanosoma cruzi. Exp Parasitol 1987; 64: 474-484.
30. Andrews NW, Robbins ES, Ley V, Hong KS & Nussenzweig V. Developmentally regulated phospholipase C-mediated release of the major surface glycoprotein of amastigotes of Trypanosoma cruzi. J Exp Med 1988; 167: 300-314.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
32. Kruisbeek AM, Shevach EM. Proliferative assays for T cell Function; In Current Protocols in Immunology, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York: Greene Publishing and Wiley-Interscience; 1991: 3.12.1-3.12.14.
33. Kanangat S, Blair P, Reddy R et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur J Immunol 1996; 26: 161-165.
34. Nau R & Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on the course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95-110.
35. Schmunis GA, Szarfman A, Coarasa L & Vainstok C. Immunoglobulin concentration in treated human acute Chagas' disease. Am J Trop Med Hyg 1978; 27: 473-477.
36. Ortiz-Ortiz L, Parks D, Rodriguez M & Weigle W. Polyclonal B lymphocyte activation during T. cruzi infection. J Immunol 1980; 124: 121-125.
37. Pyrrho AS, Moraes JL, Pecanha LM & Gattass CR. Trypanosoma cruzi. IgG1 and IgG2b are the main immunoglobulins produced by vaccinated mice. Parasitol Res 1998; 84: 333-337.
38. El Bouhdidi A, Truyens C, Rivera MT, Bazin H & Carlier Y. Trypanosoma cruzi infection in mice induces a polyisotypic hypergammaglobulinaemia and parasite-specific response involving high IgG2a concentrations and highly avid IgG1 antibodies. Parasite Immunol 1994; 16: 69-76.
39. White RG. The adjuvant effect of microbial products on the immune response. Annu Rev Microbiol 1976; 30: 579-600.
40. Schleifer K & Mansfield JM. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J Immunol 1993; 151: 5492-5497.
41. Graf BA, Nazarenko DA, Borrello MA et al. Biphenotypic B/macrophage cells express COX-1 and up-regulate COX-2 expression and prostaglandin E2 production in response to proinflammatory signals. Eur J Immunol 1999; 29: 3793-3803.
42. Almeida SR, Aroeira LS, Frymuller E et al. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int Immunol 2001; 13: 1193-1201.
43. Saxena KC, Puri A, Sumati Saxena R & Saxena RP. Macrophage migration as an index of immune status. Immunol Invest 1991; 20: 431-440.
44. Chen Y-Q, Fisher JH & Wang M-H. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: Phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol 1998; 161: 4950-4959.
45. Iwama A, Wang M-H, Yamaguchi N et al. Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein. Blood 1995; 9: 3394-3403.
46. Connelly L, Palacios-Callender M, Ameixa C, Moncada S & Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001; 15: 3873-3881.
47. Baek KJ, Thiel BA, Lucas S & Stuehr DJ. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem 1993; 268: 21120-21129.
48. 4B promotes assembly of enzyme subunits into an active dimer. Proc Nat Acad Sci 1995; 92: 11771-11775.
49. Kierszenbaum F. Immunologic deficiency during experimental Chagas' disease (Trypanosoma cruzi infection): role of adherent, nonspecific esterase-positive splenic cells. J Immunol 1982; 129: 2202-2209.
50. Tarleton RL. Trypanosoma cruzi-induced suppression of IL-2 production. II. Evidence for a role for suppressor cells. J Immunol 1988; 140: 2769-2775.
51. Hansen DS, Villacres-Eriksson M, Akerblom L et al. An immunoaffinity-purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-beta-mediated mechanism. Scand J Immunol 1998; 47: 509-516.
52. Pinge-Filho P, Tadokoro CE & Abrahamsohn IA. Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection. Cell Immunol 1999; 193: 90-97.
53. O'Garra A, Chang R, Go N, Hasting R, Haughton G & Howard M. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 1992; 22: 711-717.
54. MacMicking J, Xie QW & Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350.
55. Di Marzio P, Puddu P, Conti L, Belardelli F & Gessani S. Interferon gamma upregulates its own gene expression in mouse peritoneal macrophages. J Exp Med 1994; 179: 1731-1736.
56. Anderson CF & Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002; 72: 101-106.
57. Gerber JS & Mosser DM. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol 2001; 166: 6861-6868.
58. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-212.
59. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2002; 3: 23-35.
60. van der Veen RC. Nitric oxide and T helper cell immunity. Int Immunopharmacol 2001; 8: 1491-1500.
61. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological implications. Hypertens 2002; 6: S3-S9.
62. Akira S, Isshiki H, Sugita T et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990; 9: 1897-1906.
63. Limiroli E, Gaspani L, Panerai AE & Sacerdote P. Differential morphine tolerance development in the modulation of macrophage cytokine production in mice. J Leukoc Biol 2002; 72: 43-48.
64. Gazzinelli RT, Oswald IP, James SL & Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J Immunol 1992; 148: 1792-1796.
65. de Waal Malefyt R, Yssel H & de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754-4765.